. Author manuscript; available in PMC: 2007 Dec 10.

Published in final edited form as: Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2738–2746. doi: 10.1167/iovs.06-1023

Table 1.

Inhibitors used in this study^*

Inhibitor	Protein Target
U0126	MEK
SB202190	P38
Sp600125	JNK
AG490	Jak2
Genistein	PTK
Ro318220	PKC
CAPE	NF-κB
Ly294002	PI3K
Nac	ROS
DPI	ROS
BAPTA/AM	Calcium chelator

MEK, mitogen-activated protein kinase; JNK, c-Jun NH2-terminal kinase; jak2, Janus kinase 2; PTK, protein tyrosine kinase; PKC, protein kinase C; NF-κB, nuclear factor-κB; PI3K, phosphatidylinositol 3-kinase; Nac, N-acetyl-cysteine; DPI, diphenyleneiodonium chloride; ROS, reactive oxygen species; BAPTA/AM, 1,2-bis-(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid/acetoxy-methyl ester.